WHO Tackles Submission Of Insufficient Or False Data By Pharma
This article was originally published in The Gold Sheet
Executive Summary
The World Health Organization has issued guidance on data integrity that provides a comprehensive, global perspective on the issue.
You may also be interested in...
CRO Inspection Fall-Out: Semler's Clients Have To Repeat Studies
Data integrity spotlight expands beyond cGMP as FDA finds Semler manipulated study subject samples in bioequivalence studies conducted at its Bangalore facility.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.